Compare · LNTH vs NNNN
LNTH vs NNNN
Side-by-side comparison of Lantheus Holdings Inc. (LNTH) and Anbio Biotechnology (NNNN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LNTH and NNNN operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- LNTH is the larger of the two at $6.65B, about 11.9x NNNN ($558.3M).
- Over the past year, LNTH is up 93.7% and NNNN is down 72.3% - LNTH leads by 166.0 points.
- LNTH has hit the wire 12 times in the past 4 weeks while NNNN has been quiet.
- LNTH has more recent analyst coverage (18 ratings vs 0 for NNNN).
- Company
- Lantheus Holdings Inc.
- Anbio Biotechnology
- Price
- $101.75+0.16%
- $3.89+1.57%
- Market cap
- $6.65B
- $558.3M
- 1M return
- +2.05%
- +16.99%
- 1Y return
- +93.65%
- -72.33%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2025
- News (4w)
- 12
- 0
- Recent ratings
- 18
- 0
Lantheus Holdings Inc.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for opioid-induced constipation. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical. It provides Thallium-201 to detect cardiovascular disease; Gallium-67 to detect various infections and cancerous tumors; and Quadramet for severe bone pain associated with osteoblastic metastatic bone lesions. The company also develops PyL for prostate cancer; flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroendocrine tumors; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic; 1404, a Tc-99m labeled small molecule; PSMA-AI, an AI-based imaging analysis technology; and leronlimab, an investigational humanized monoclonal antibody. It serves radiopharmacies, PET manufacturing facilities, integrated delivery networks, hospitals, clinics, and group practices. The company has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM Toyama Chemical Co. Ltd.; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Latest LNTH
- SEC Form SCHEDULE 13G filed by Lantheus Holdings Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Lantheus Holdings Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Lantheus Holdings Inc.
- Lantheus Presents Data from Two Pivotal Phase 3 Studies of TAUKLARIFY (Florquinitau F 18 Injection) PET Imaging in Early Alzheimer’s Disease
- Amendment: SEC Form SCHEDULE 13D/A filed by Lantheus Holdings Inc.
- PharmaLogic to Acquire Lantheus' CDMO Business and Springfield, New Jersey Manufacturing Facility
- Amendment: SEC Form SCHEDULE 13G/A filed by Lantheus Holdings Inc.
- SEC Form 10-Q filed by Lantheus Holdings Inc.
- Lantheus Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals
Latest NNNN
- SEC Form F-3ASR filed by Anbio Biotechnology
- SEC Form 3 filed by new insider Zhang Michael W.C
- SEC Form 3 filed by new insider Hsu David H
- SEC Form 6-K filed by Anbio Biotechnology
- SEC Form 6-K filed by Anbio Biotechnology
- Amendment: SEC Form 20-F/A filed by Anbio Biotechnology
- SEC Form 3 filed by new insider Song Suki
- SEC Form 3 filed by new insider Hartzler Nancy
- SEC Form 3 filed by new insider Lau Michael
- SEC Form 3 filed by new insider Tian Chris